Role of mycophenolate mofetil in the treatment of lupus nephritis

Abstract: Mycophenolate mofetil (MMF) is an immunosuppressive drug successfully used for the prevention of acute and chronic rejection of renal allografts, as well as in the therapy of glomerular disorders. We treated three groups of patients with lupus nephritis: the first group of patients had a high histologic activity index (AI), 13.4 ± 2.34; the second group of patients had a high histologic chronicity index (CI), 6.0 ± 0.7; and the third group consisted of only two patients, one with low AI (3.5) and another with low CI (1.5). The patients were treated for 2 years. MMF was initiated at a dose of 2  g/daily for the first 6 months and the dose was decreased to 1.5  g/daily for the further 18 months. Steroids, 0.4  mg/kg/day, were the concomitant therapy for the first 6 months, with slow tapering for the further 18 months. Patients with high AI presented significant decrease of serum creatinine after 2 years, 286 ± 112.95 to 131.2 ± 44.65 μmol/L. Two of the patients, with acute oligoanuria, were withdrawn from dialysis treatment. Significant improvement was also noted, 6.97 ± 1.81 to 0.9 ± 0.31  g/day. Patients with high CI had nonsignificant decrease of serum creatinine, 178.5 ± 47.73 to 129.25 ± 22.88 μmol/L, and significant improvement of proteinuria, 4.63 ± 1.57 to 1.14 ± 0.39  g/day. The patient with low AI showed recovery of renal function (serum creatinine from 196 to 72 μmol/L) and alleviation of proteinuria, 7.93 to 3.4  g/day. The patient with low CI did not respond to the therapy and renal function slowly worsened. MMF has emerged as a promising therapeutic approach for both the induction and maintenance phase in patients with lupus nephritis.